FilingReader Intelligence
Biocon Biologics gains FDA approval for diabetes treatment
July 15, 2025 at 06:29 PM UTC•By FilingReader AI
Biocon Biologics announced U.S. FDA approval for Kirsty™ (Insulin Aspart-xjhz) as the first interchangeable biosimilar to NovoLog®. This expands its biosimilar insulin portfolio alongside Semglee®.
The U.S. Insulin Aspart market was approximately $1.9bn in 2024. Kirsty™ has been available in Europe and Canada since 2022.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:BIOCON•Bombay Stock Exchange
News Alerts
Get instant email alerts when Biocon publishes news
Free account required • Unsubscribe anytime